Clinical relevance of JAK2 (V617F) mutant allele burden

被引：60
|
作者：
Passamonti, Francesco [1 ]
Rumi, Elisa [1 ]
机构：
[1] Univ Pavia, Fdn IRCCS Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 01期
关键词：
POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; WILD-TYPE; MUTATION; JAK2V617F; MYELOFIBROSIS; JAK2(V617F); RISK; PROGRESSION; GRANULOCYTE;
D O I：
10.3324/haematol.2008.001271
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：7 / 10
页数：4
相关论文
共 50 条
  • [41] Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow
    Larsen, T. S.
    Pallisgaard, N.
    Moller, M. B.
    Hasselbalch, H. C.
    LEUKEMIA, 2008, 22 (01) : 194 - 195
  • [42] JAK2 V617F Allele Burden in Non-CML Classical Subtypes of Myeloproliferative Neoplasms (MPN)
    Gober-Wilcox, J.
    Vennapusa, B.
    Pierce, J.
    Vasef, M. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 581 - 581
  • [43] JAK2 V617F Mutation Allele Burden (MAB) and Its Correlation with Hematologic Characteristics in Myeloproliferative Neoplasms
    Kim, David Y.
    Tariq, Hamza
    Brown, Alan F.
    Vadlamudi, Kumari
    Wang, Yao
    Ikoma, Shohei
    Holder, Kenneth N.
    Higgins, Russell A.
    Fan, Hongxin
    BLOOD, 2017, 130
  • [44] A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs
    Link-Lenczowska, Dorota
    Pallisgaard, Niels
    Cordua, Sabrina
    Zawada, Magdalena
    Czekalska, Sylwia
    Krochmalczyk, Dorota
    Kandula, Zuzanna
    Sacha, Tomasz
    ANNALS OF HEMATOLOGY, 2018, 97 (12) : 2299 - 2308
  • [45] Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
    Antonioli, E
    Guglielmelli, P
    Pancrazzi, A
    Bogani, C
    Verrucci, M
    Ponziani, V
    Longo, G
    Bosi, A
    Vannucchi, AM
    LEUKEMIA, 2005, 19 (10) : 1847 - 1849
  • [46] Clinical characteristics of JAK2 V617F positive myeloproliferative diseases
    Andrikovics, H.
    Szilvasi, A.
    Meggyesi, N.
    Tamaska, J.
    Halm, G.
    Lueff, S.
    Nahajevszky, S.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Tordai, A.
    Masszi, T.
    BLOOD REVIEWS, 2007, 21 : S124 - S124
  • [47] Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
    E Antonioli
    P Guglielmelli
    A Pancrazzi
    C Bogani
    M Verrucci
    V Ponziani
    G Longo
    A Bosi
    A M Vannucchi
    Leukemia, 2005, 19 : 1847 - 1849
  • [48] Aquagenic pruritus and the JAK2 V617F mutation
    Langabeer, S. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (03) : E33 - E33
  • [49] JAK2 (V617F) mutation in healthy individuals
    Passamonti, Francesco
    Rumi, Elisa
    Pietra, Daniela
    Lazzarino, Mario
    Cazzola, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) : 678 - 679
  • [50] JAK2 V617F mutation and the myeloproliferative disorders
    Vainchenker, William
    Casadevall, Nicole
    HEMATOLOGIE, 2006, 12 (01): : 3 - 7
12345